Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial

@inproceedings{Bramwell2013AssessmentOO,
  title={Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial},
  author={Vivien H. C. Bramwell and Alan B. Tuck and Judith-Anne W Chapman and Pieter H. Anborgh and Carl O. Postenka and Waleed Al-Katib and Lois E. Shepherd and Lei Han and Carolyn F G Wilson and Kathleen I. Pritchard and Michael N. Pollak and Ann F. Chambers},
  booktitle={Breast Cancer Research},
  year={2013}
}
Osteopontin (OPN) is a malignancy-associated glycoprotein that contributes functionally to tumor aggressiveness. In metastatic breast cancer, we previously demonstrated that elevated OPN in primary tumor and blood was associated with poor prognosis. We measured OPN in plasma by ELISA, and in tumors by immunohistochemistry, in 624 (94%) and 462 (69%), respectively, of 667 postmenopausal women with hormone responsive early breast cancer treated by surgery followed by adjuvant treatment with… CONTINUE READING
Highly Cited
This paper has 19 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…